From: The market trend analysis and prospects of cancer molecular diagnostics kits
Category / Year | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | CAGR |
---|---|---|---|---|---|---|---|---|
Breast cancer | 375.4 | 383.8 | 531.3 | 735.5 | 1018.2 | 1409.5 | 1951.2 | 38.4% |
Colorectal cancer | 346.5 | 391.6 | 531.1 | 720.4 | 977.1 | 1325.2 | 1797.4 | 35.6% |
Cervical cancer | 259.0 | 267.6 | 304.1 | 345.5 | 392.6 | 446.2 | 507.0 | 13.6% |
Lung cancer | 113.6 | 128.2 | 197.0 | 302.8 | 465.5 | 715.4 | 1099.6 | 53.7% |
Precancer | 104.5 | 124.9 | 188.3 | 283.7 | 427.7 | 644.6 | 971.5 | 50.7% |
Prostate cancer | 99.2 | 117.2 | 170.1 | 247.0 | 358.6 | 520.6 | 755.8 | 45.2% |
Melanoma | 92.0 | 104.8 | 134.6 | 172.8 | 221.8 | 284.8 | 365.7 | 28.4% |
Leukemia | 74.5 | 88.3 | 130.4 | 192.6 | 284.4 | 419.9 | 620.1 | 47.7% |
Lymphoma | 42.9 | 51.9 | 91.0 | 159.6 | 279.8 | 490.7 | 860.4 | 75.4% |
Pancreatic cancer | 26.4 | 32.7 | 47.0 | 67.6 | 97.1 | 139.6 | 200.6 | 43.7% |
Bladder cancer | 21.2 | 25.9 | 36.4 | 51.3 | 72.2 | 101.6 | 142.9 | 40.7% |
Chest cancer | 19.1 | 21.8 | 35.3 | 57.3 | 92.9 | 150.7 | 244.3 | 62.1% |
Brain cancer | 18.4 | 24.2 | 34.2 | 48.3 | 68.3 | 96.5 | 136.4 | 41.3% |
Thyroid cancer | 12.6 | 16.3 | 28.2 | 48.9 | 84.7 | 146.6 | 253.9 | 73.2% |
Kidney cancer | 11.7 | 15.6 | 27.6 | 49.0 | 86.8 | 153.9 | 272.8 | 77.2% |
Ovarian cancer | 6.7 | 9.5 | 16.4 | 28.3 | 49.0 | 84.6 | 146.1 | 72.7% |
Stomach cancer | 0.0 | 3.6 | 7.9 | 17.2 | 37.5 | 81.9 | 178.8 | 118.4% |
Other | Â | Â | Â | Â | Â | Â | 157.8 | Â |
Total | 1623.7 | 1807.9 | 2511.1 | 3527.8 | 5014.1 | 7212.2 | 10,662.3 | 42.6% |